Brief: Mezzion Pharmaceuticals Reaches Key Enrollment Milestone In World's Largest Fontan Clinical Trial
31/07/2025 14:39
July 31 (Reuters) - Mezzion Pharma Co Ltd 140410.KQ: MEZZION PHARMACEUTICALS REACHES KEY ENROLLMENT MILESTONE IN WORLD'S LARGEST FONTAN CLINICAL TRIAL Source text: ID:nPn60j0xwa Further company coverage: 140410.KQ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mezzion Pharma
See all newsBrief: Mezzion Secures Strategic Financing To Support Advancement Of Global Phase 3 Fuel-2 Trial In Fontan Patients
Brief: Mezzion Reports Pre-Ind FDA Feedback On The Development Of Udenafil In Adpkd
Brief: Mezzion Pharmaceuticals Appoints Ridwan Shabsigh As President & Chief Operating Officer
Brief: Mezzion Pharmaceuticals Reaches Key Enrollment Milestone In World's Largest Fontan Clinical Trial
Brief: Mezzion Pharmaceuticals Announces Dr Rahul Rathod As Global Principal Investigator For The Confirmatory Pivotal Phase 3 Trial FUEL-2